In vivo analysis of chronic phosphodiesterase-5 inhibition with sildenafil in penile erectile tissues: No tachyphylaxis effect

Journal of Urology

Volumn 174, Issue 4 I, 2005, Pages 1493-1496

  Musicki, Biljana ^a   Champion, Hunter C ^a   Becker, Robyn E ^a   Kramer, Melissa F ^a   Liu, Tongyun ^a   Sezen, Sena F ^a   Burnett, Arthur L ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Aging; Impotence; Penis; Phosphodiesterase inhibitors; Rats, inbred F344

Indexed keywords

CYCLIC GMP; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; SODIUM CHLORIDE;

AGED; AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CHRONIC DISEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENZYME INHIBITION; IMPOTENCE; LONG TERM CARE; MALE; MALE SEXUAL DYSFUNCTION; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT OUTCOME;

EID: 24944580830     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000173006.47623.2c     Document Type: Article

References (20)

1. Burnett, A. L., Lowenstein, C. J., Bredt, D. S., Chang, T. S. and Snyder, S. H.: Nitric oxide: a physiologic mediator of penile erection. Science, 257: 401, 1992
2. Hurt, K. J., Musicki, B., Palese, M. A., Crone, J. K., Becker, R. E., Moriarity, J. L. et al: Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci USA, 99: 4061, 2002
3. Burnett, A. L.: Role of nitric oxide in the physiology of erection. Biol Reprod, 52: 485, 1995
4. Boolell, M., Allen, M. J., Ballard, S. A., Gepi-Attee, S., Muirhead, G. J., Naylor, A. M. et al: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res, 8: 47, 1996
5. Ballard, S. A., Gingell, C. J., Tang, K., Turner, L. A., Price, M. E. and Naylor, A. M.: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol, 159: 2164, 1998
6. Moreland, R. B., Goldstein, I. and Traish, A.: Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci, 62: PL309, 1998
7. Gemalmaz, H., Waldeck, K., Chapman, T. N., Tuttle, J. B., Steers, W. D. and Andersson, K.-E.: In vivo and in vitro investigation of the effects of sildenafil on rat cavernous smooth muscle. J Urol, 165: 1010, 2001
8. Ueno, N., Iwamoto, Y., Segawa, N., Kinoshita, M., Ueda, H. and Katsuoka, Y.: The effect of sildenafil on electrostimulation-induced erection in the rat model. Int J Impot Res, 14: 251, 2002
9. El-Galley, R., Rutland, H., Talic, R., Keane, T. and Clark, H.: Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol, 166: 927, 2001
10. Gonzalgo, M. L., Brotzman, M., Trock, B. J., Geringer, A. M., Burnett, A. L. and Jarow, J. P.: Clinical efficacy of sildenafil citrate and predictors of long-term response. J Urol, 170: 503, 2003
11. Steers, W., Guay, A. T., Leriche, A., Gingell, C., Hargreave, T. B., Wright, P. J. et al: Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment. Int J Impot Res, 13: 261, 2001
12. De Young, L., Yu, D., Freeman, D. and Brock, G. B.: Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. Int J Impot Res, 15: 347, 2003
13. Lin, G., Xin, Z.-C., Lue, T. F. and Lin, C.-S.: Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism. J Urol, 170: S15, 2003
14. Lin, C. S., Chow, S., Lau, A., Tu, R. and Lue, T. F.: Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int J Impot Res, 14: 15, 2002
15. Garban, H., Vernet, D., Freedman, A., Rajfer, J. and Gonzalez-Cadavid, N.: Effect of aging on nitric oxide-mediated penile erection in rats. Am J Physiol, 268: H467, 1995
16. Walker, D. K., Ackland, M. J., James, G. C., Muirhead, G. J., Ranee, D. J., Wastall, P. et al: Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica, 29: 297, 1999
17. Champion, H. C., Bivalacqua, T. J., Takimoto, E., Kass, D. A. and Burnett, A. L.: Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA, 102: 1661, 2005
18. Salonia, A., Rigatti, P. and Montorsi, F.: Sildenafil in erectile dysfunction: a critical review. Curr Med Res Opin, 19: 241, 2003
19. Blount, M. A., Beasley, A., Zoraghi, R., Sekhar, K. R., Bessay, E. P., Francis, S. H. et al: Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity and cGMP stimulation. Mol Pharmacol, 66: 144, 2004
20. Mondaini, N., Ponchietti, R., Muir, G. H., Montorsi, F., Di Loro, F., Lombardi, G. et al: Sildenafil does not improve sexual function in men without erectile dysfunction but does reduce the postorgasmic refractory time. Int J Impot Res, 15: 225, 2003